Central Garden & Pet Company (CENT): what the price requires
The current priced-in claim for Central Garden & Pet Company (CENT) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/CENT
Headline
| Field | Value |
|---|---|
| Ticker | CENT |
| Company | Central Garden & Pet Company |
| Current price | $43.09/sh |
| Composition | Other garden products 26% / Other pet products 19% / Other manufacturers' products 21% / Dog & cat products 19% / Wild bird 15% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Multiple paid | 14x operating income |
The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.
Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 7% sits below it).
Reconcile: at the x-ray's 9.3% required return this reads ~4.5%/yr; the models below use their own rates.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | -0.58σ |
| cohort percentile (of 210 peers) | 28 |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple and growth-DCF.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 1.36x | 5 | expensive |
| Earnings | 1.29x | 5 | expensive |
| Relative | 0.79x | 5 | justifies |
| Growth | 0.84x | 3 | justifies |
Families that justify the price: Relative, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.3%); the inversion above states its own rate.
Per-Model Detail (n=18)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $65.30 | 0.66x | yes | FCF base $0.3B, growth 0% (input: historical growth), terminal g 0.5%, WACC 6.3%, 5yr projection |
| DCF Exit Multiple | Growth | $51.56 | 0.84x | yes | Exit EV/EBITDA: 8.0x / 10.0x / 12.0x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $52.00 | 0.83x | yes | P/E 18x (static sector reference · 2026-04), scenarios: 15.2x / 18.0x / 20.8x (bear / base = reference held flat / bull), EV/EBITDA 12x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $29.96 | 1.44x | yes | BV/sh $26.69, ROE (TTM) 10.4%, ke 9.3% |
| Two-Stage Excess Return | Asset | $31.69 | 1.36x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $27.82 | 1.55x | yes | Rev $3.2B, growth 0% (input: historical growth; tapered), Terminal P/S: 0.7x / 0.8x / 1.0x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $54.55 | 0.79x | yes | EPS $2.75, growth 20% (input: historical EPS growth), PEG=0.78 (Undervalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $33.15 | 1.30x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.23B × (1−23%) / WACC 6.3% → EPV (no growth) |
| Residual Income | Asset | $32.01 | 1.35x | yes | BV $26.69 + 5yr PV of (ROE (TTM) 10.4% − Kₑ 9.3%) × BV; BV grows 6.7%/yr |
| Graham Number | Asset | $40.64 | 1.06x | yes | √(22.5 × EPS $2.75 × BVPS $26.69) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $54.13 | 0.80x | yes | EBITDA $0.34B × sector EV/EBITDA 12.0x |
| FCF Yield | Earnings | $36.98 | 1.17x | yes | FCF $282.4M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $33.31 | 1.29x | yes | SBC-adj FCF $0.26B (FCF $0.28B − SBC $0.02B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $88.73 | 0.49x | yes | EPS $2.75 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $15.28 | 2.82x | yes | BV $26.69 × (ROIC 3.6% / WACC 6.3%) |
| P/Sales Sector | Relative | $127.80 | 0.34x | yes | Revenue $3.16B × sector P/S 2.5x |
| PEG Fair Value | Relative | $81.83 | 0.53x | yes | EPS $2.75 × (PEG 1.5 × growth 19.8% (input: historical EPS growth)) → PE 29.8x |
| Earnings Yield | Earnings | $29.73 | 1.45x | yes | EPS $2.75 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $539.5m |
| Net debt / NOPAT (after-tax) | 2.82x |
| Net debt / operating income (pre-tax) | 2.16x |
| Share count CAGR (buyback) | -3.0% |
| Burning cash | no |
Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.
Bullet Takeaways
At $43.16 the price pays about 14x company-wide operating income, a multiple low enough that it sits below what even a 5% per year decline in operating profit would warrant. This is priced as a no-growth, possibly shrinking business.
Most valuation families land above the price. Only the most conservative future-market-cap and excess-return floors sit lower.
Management is voting with the balance sheet. The board added $100 million to the buyback calling the shares undervalued, fiscal Q2 2026 EPS rose to $1.28 from $0.98, and the company reaffirmed full-year non-GAAP EPS guidance of $2.70 or better while running a margin-focused Cost and Simplicity program. The question is whether a cheap multiple reflects a durable cash machine or a slow-growth consumer business near a cyclical peak.
Bull Case
Capital allocation is the clearest signal in this story, so start there. Central Garden & Pet generates steady cash from a portfolio of garden and pet brands, and management is deploying that cash in the two ways that compound value for a low-growth business: buying back stock when it is cheap and bolting on accretive acquisitions. The board recently added $100 million to the repurchase authorization explicitly because it considers the shares undervalued, leaving $128 million authorized at quarter end. A company buying its own stock at roughly 14x operating income, with management on record calling the price undervalued, is putting shareholder cash to work at a high implied return. The 10-K describes the acquisition discipline in the same vein, targeting 'growth- and margin-accretive, brand-focused companies led by strong management teams' to build scale in core categories and fill whitespace (FY2025 10-K, accession 0000887733-25-000041).
The operating performance behind the cash is improving, not deteriorating. Fiscal Q2 2026 net sales rose to $906 million from $834 million, and GAAP diluted EPS climbed to $1.28 from $0.98, a meaningful jump driven by the Cost and Simplicity agenda that management credits for record bottom-line results and continued margin expansion. The company reaffirmed full-year non-GAAP EPS guidance of $2.70 or better. For a mature consumer business, mid-single-digit sales growth paired with expanding margins and disciplined cost-out is exactly the profile that turns a flat top line into rising earnings per share, and the buyback amplifies that into per-share growth the revenue line alone would not produce.
The valuation gap is the third leg. The price implies essentially no growth, sitting below what even a 5% annual decline in operating profit would warrant, yet the business is growing EPS and expanding margins. The 10-K notes the structural advantages that support that durability, with 'major retailers value our national scope and operational capabilities while independent retailers value our premium portfolio and service levels.' A diversified branded-products company with retailer relationships on both ends of the market, priced as if it were in decline while it is actually executing, is the kind of unexciting compounder that rewards patience.
Bear Case
The sector-cycle question is whether the recent earnings are sustainable or near a peak, and there are reasons for caution. Garden and pet products are consumer-discretionary at the margin: garden spending tracks housing turnover, weather, and home-improvement budgets, while pet adoption and premium-pet spending surged during the pandemic and have been normalizing since. The margin expansion management celebrates came partly from the Cost and Simplicity program, which is one-time cost-out by nature. Cost-out improves margins until the easy cuts are done, and then earnings growth has to come from volume again. If fiscal 2026 represents a margin high-water mark reached through cost discipline against a flat-to-soft demand backdrop, the cheap multiple may be the market correctly pricing limited growth from here, not a mistake.
Customer concentration is the structural risk underneath the brand portfolio. Central sells through major retailers, and the 10-K's own framing, that 'major retailers value our national scope and operational capabilities,' is the polite version of a relationship where a handful of large chains control shelf access and pricing power. A branded consumer company that depends on big-box and mass retailers faces constant pressure on price, private-label substitution (which Central itself supplies, cannibalizing its own brands), and the risk that a single large customer shifts allocation. The diversification across garden and pet helps, but both ends funnel through the same retail gatekeepers.
The third issue is that this is a roll-up carrying leverage, and roll-ups are only as good as the deals. Net debt sits near $539 million against trailing operating income near $259 million, roughly 2x, with interest coverage near 4.5x, which is manageable but not trivial for a slow-grower. The acquisition strategy the bull case applauds is also a risk: integration missteps, paying up in a competitive deal market, or a misjudged adjacency would each destroy value. And a low multiple on a leveraged consumer business is not automatically a bargain. If volumes soften in a weak consumer environment, operating income can fall faster than the headline suggests, and a price that looks cheap at 14x today would look fair at 14x on lower earnings. The bull read requires believing the discount is sentiment; the bear read is that the market is pricing a business at or past its cyclical earnings peak.
Valuation
Central Garden & Pet inverts to a no-growth price. At about 14x company-wide operating income, the multiple is low enough that the price sits below what even a 5% per year decline in operating profit would warrant, computed at a 7% cost of capital with 4% terminal growth. This is a bound rather than a solved growth rate: the market is not asking the business to grow, it is pricing in mild decline. Against that, the company is growing EPS and expanding margins, which is the core of the disagreement.
The method families lean above the price. The forward-growth methods land near $52 to $65 (perpetual-growth DCF, exit-multiple DCF), the peer-multiple methods near $52 to $55 (relative valuation, EV/EBITDA, Peter Lynch), and the earnings-power methods near $30 to $37. The conservative outliers are the discounted-future-market-cap method near $28 and the excess-return frames near $30 to $32. That spread is modest and reassuring rather than dramatic: this is not a name where one family screams expensive and another screams cheap; most frames cluster in the high-$40s to low-$50s, suggesting the price carries a discount to a reasonable central estimate. The valuation question is therefore narrow and concrete. If the recent margin expansion is durable and the buyback keeps shrinking the share count, the no-growth price is a genuine discount on a steady compounder. If the margins are a cyclical peak achieved through one-time cost-out against soft demand, then the cheap multiple is appropriate and the upside is limited. The capital-allocation behavior, buying back stock that management calls undervalued, is the company itself betting on the first interpretation.
Catalysts
The fiscal 2026 results were the recent catalyst and they read constructively. Q2 net sales rose to $906 million from $834 million, GAAP diluted EPS climbed to $1.28 from $0.98, and management reaffirmed full-year non-GAAP EPS guidance of $2.70 or better, crediting the Cost and Simplicity agenda for record bottom-line results and continued margin expansion. The board added $100 million to the buyback authorization, calling the shares undervalued, with $128 million remaining at quarter end. The next prints are a test of whether margin expansion continues once the easier cost-out is captured and whether top-line growth holds in a normalizing consumer environment.
The forward watch items are demand cyclicality and capital deployment. Garden sales are seasonal and weather-sensitive, and pet spending is normalizing off pandemic highs, so the consumer backdrop and the spring garden season are the demand variables that matter most. On capital allocation, the pace of buybacks against the undervalued thesis, and any new bolt-on acquisitions in core categories or adjacencies, would each move the per-share earnings trajectory. For a name priced for no growth, the catalysts that re-rate it are sustained EPS growth from margins and the share count, accretive deals, and evidence that fiscal 2026 is a step in a trend rather than a cyclical peak.
Sources: Central Garden & Pet Q2 2026 8-K press release (SEC), Central increases buyback by $100M, sees shares undervalued (Investing.com), Central FY2025 results and fiscal 2026 outlook (IR), Central FY2025 10-K.
Peer Cohorts (Per Segment, With Filing Citations)
Pet / Garden (reported)
- SPB (Spectrum Brands Holdings, Inc.)
- (no filing in the citation store)
- SMG (Scotts Miracle-Gro Co)
- (no filing in the citation store)
- FRPT (FRESHPET, INC.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.